| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/17/2003 | WO2003057165A2 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
| 07/17/2003 | WO2003057162A2 Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057146A2 Novel compositions and methods for cancer |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057136A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | WO2003057134A2 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | WO2003057130A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 07/17/2003 | WO2003056913A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | WO2003056899A2 Nitric oxide donors for treatment of disease and injury |
| 07/17/2003 | WO2003039488A3 A method for treating inflammatory bowel disease |
| 07/17/2003 | WO2003031595A3 Molecules for disease detection and treatment |
| 07/17/2003 | WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis |
| 07/17/2003 | WO2003020371A3 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use |
| 07/17/2003 | WO2002076434A3 Nicotinic receptor agonists for the treatment of inflammatory diseases |
| 07/17/2003 | WO2002074335A3 Equine herpesvirus vaccine |
| 07/17/2003 | WO2002072008A3 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002040683A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/17/2003 | WO2002031134A3 Novel serine protease genes related to dppiv |
| 07/17/2003 | WO2002029060A9 Hematopoietin receptors hpr1 and hpr2 |
| 07/17/2003 | WO2002026998A3 Hydrolases |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2002017858A9 Role of fosb in bone formation |
| 07/17/2003 | WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 07/17/2003 | WO2002009677A3 Method to treat infectious diseases and/or to enhance antimicrobial efficacy of drugs |
| 07/17/2003 | US20030135196 Irrigating via the flow pathway the area of the hemorrhage with a synthetic cerebrospinal fluid to reduce an indication of the presence of blood in effluent from the outflow catheter. |
| 07/17/2003 | US20030134903 Substituted aminoalkanoate or substituted aminoalkyl alkanoate as a penetration enhancer a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. |
| 07/17/2003 | US20030134893 Combination chemotherapy |
| 07/17/2003 | US20030134889 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 07/17/2003 | US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 07/17/2003 | US20030134868 Prevention of addiction in pain management |
| 07/17/2003 | US20030134865 Modulation of histone deacetylase |
| 07/17/2003 | US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 07/17/2003 | US20030134830 Bioavailable prodrugs of androgenic steroids and related method |
| 07/17/2003 | US20030134828 Composition and method for increasing in vivo androgen concentration |
| 07/17/2003 | US20030134825 Food product supplemented with proteoglycan precursors |
| 07/17/2003 | US20030134821 Promoters of neural regeneration |
| 07/17/2003 | US20030134820 Promoting neural cell growth and/or regeneration. The general methods involve contacting with an activator of a cyclic nucleotide dependent protein kinase a neural cell subject to growth repulsion mediated by a neural cell growth repulsion |
| 07/17/2003 | US20030134812 Bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using alpha 1d-adrenergic receptor ( alpha 1dAR) antagonists. The invention further relates to a method of screening compounds |
| 07/17/2003 | US20030134811 Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134805 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs |
| 07/17/2003 | US20030134802 Novel effectors of dipepetidyl peptidase IV |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134777 Treating or preventing arrhythmias in a human subject comprising the administration of an effective amount of a calcium/calmodulin-dependent protein kinase inhibitor. Also provided are pharmaceutical compositions as antiarrhythmia |
| 07/17/2003 | US20030134775 Therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic |
| 07/17/2003 | US20030134344 Her2 gene amplification as detected by fluorescence in situ hybridization |
| 07/17/2003 | US20030134334 Use of vascular endothelial growth factor (VEGF) |
| 07/17/2003 | US20030134332 Diagnosis of endothelial dysfunction by nitric oxide bioactivity index |
| 07/17/2003 | US20030134319 Amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides |
| 07/17/2003 | US20030134315 Testing a sample from a cancer patient for the expression of a negative signal transduction factor (NSTF) and for the expression of a positive signal transduction factor (PSTF), selecting chemotherapeutic agent for treatment based on above |
| 07/17/2003 | US20030134314 Assaying the ability of specific polypeptide activity, thereby identifying a compound capable of treating a hematologic disorder |
| 07/17/2003 | US20030134308 Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| 07/17/2003 | US20030134301 Nucleic acids, their expression products and pathways involved in pain, and their use in screening for molecule that can alleviate pain |
| 07/17/2003 | US20030134282 Quantitative analysis of tissue gene expression; amplification; polymerase chain reaction |
| 07/17/2003 | US20030133996 Ruminant animal feed, and mineral supplement and method of use |
| 07/17/2003 | US20030133994 Administration of a combination regimen of a platinum agent, a taxane agent, and a formula I toxicity-reducing agent |
| 07/17/2003 | US20030133992 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| 07/17/2003 | US20030133991 Composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in carrier, which, when applied to open wound, modulates activity of MMP-2 and/or MMP- 9 in wound; ulcer treatment |
| 07/17/2003 | US20030133977 Method of systemically delivering SSRIs |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133969 Topical agent capable of disrupting membrane or protein conformation in a target cell, tissue or microbe; does not contain nonoxynol-9, benzalkonium chloride or menfegol |
| 07/17/2003 | US20030133951 Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 07/17/2003 | US20030133932 Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 07/17/2003 | US20030133931 Combining a putative modulator compound of mammalian histamine H4 receptor protein activity with mammalian histamine H4 receptor protein and a known histamine receptor H4 ligand, measuring the effect of the modulator on the protein |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133929 Draining blood from the animal, separating blood cells from plasma, contacting plasma with a solvent in which lipids are soluble, separating plasma to reintroduce it into the animal, separating dissolved lipids |
| 07/17/2003 | US20030133925 Monobactam compositions and methods of use thereof |
| 07/17/2003 | US20030133902 Method of making phosphate-binding polymers for oral administration |
| 07/17/2003 | US20030133889 Treating skin and/or mucous membrane by applying an aqueous solution of ascorbic acid or a derivative stabilized by the polymer; oxidation resistance; sunscreen agents; combatting pollution, sunburn; free radical scavengers; skin tone |
| 07/17/2003 | US20030133877 For inhibiting a cerebral neurovascular disorder, a muscular headache, or cerebral inflammation; administering to patient using intranasal drug delivery device |
| 07/17/2003 | US20030133875 Assay for screening candidate drug for the treatment of inflammatory diseases and methods for treating the same |
| 07/17/2003 | CA2767061A1 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | CA2472893A1 Cancer treatment |
| 07/17/2003 | CA2472882A1 Modification of feeding behavior |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472282A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | CA2472198A1 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472151A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471932A1 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | CA2471880A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471868A1 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | CA2471846A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 07/17/2003 | CA2471840A1 Novel compositions and methods for cancer |
| 07/17/2003 | CA2471754A1 Androgen receptor antagonist |
| 07/17/2003 | CA2471566A1 Combination of mtp inhibitors or apob-secretion inhibitors with fibrates for use as pharmaceuticals |
| 07/17/2003 | CA2471509A1 Combinations comprising epothilones and anti-metabolites |
| 07/17/2003 | CA2471504A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | CA2471432A1 Nonhuman model animal lacking the ability to control lymphocyte migration |
| 07/17/2003 | CA2471214A1 The use of histamine h4 receptor antagonist for the treatment of inflammatory response |
| 07/17/2003 | CA2471204A1 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | CA2470495A1 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | CA2469162A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 07/17/2003 | CA2468888A1 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |